Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
Jones, Mark A., B.Sc., Ph.D.
Del Mar, Chris
Hama, Rokuro, M.D.
Thompson, Matthew J.
PublisherBMJ Publishing Group
MetadataShow full item record
CitationJefferson, T., Jones, M.A., Doshi, P., et al. (2014). Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open, 4(9). DOI: 10.1136/bmjopen-2014-005253
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6585
- Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
- Authors: Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ
- Issue date: 2014 Apr 9
- Research transparency: a moral obligation.
- Issue date: 2014 Jun
- Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review.
- Authors: Jørgensen L, Gøtzsche PC, Jefferson T
- Issue date: 2018 Jan 18
- Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews.
- Authors: Vale CL, Tierney JF, Burdett S
- Issue date: 2013 Apr 22
- Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data.
- Authors: Heneghan CJ, Onakpoya I, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T
- Issue date: 2016 May